Ekso Bionics (EKSO) Reports Preliminary Q4 Result
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall Street indexes fall, with Iran and earnings season in focus
- Oil settles 1% higher as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results
January 8, 2019 8:01 AM ESTRICHMOND, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2018.
Total revenue for the fourth quarter of 2018 is an estimated $3.3 million reflecting year-over-year growth of 32% compared to total revenue of $2.5 million in the fourth quarter of 2017. Total revenue for the fourth quarter of 2018 includes approximately $2.4 million in medical revenue. The Company shipped 25 EksoGT systems in the fourth quarter ended... More
